Please try another search
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Name | Age | Since | Title |
---|---|---|---|
Laurent Levy | 49 | 2017 | Chairman of Supervisory Board |
Agnès Tixier | 54 | 2019 | Member of Supervisory Board |
Bruno Guigas | - | - | Member of Scientific & Medical Board |
Jean-Marie Bard | - | - | Member of Scientific & Medical Board |
André Marette | - | - | Member of Scientific & Medical Board |
Nathalie Boisseau | - | - | Member of Scientific & Medical Board |
Samy Hadjadj | - | - | Member of Scientific & Medical Board |
Jean Zetlaoui | - | 2017 | Member of Supervisory Board |
Thierry Maugard | - | - | Member of Scientific & Medical Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review